Trial Profile
A Multicenter Study to Evaluate the Anti-viral Activity of an Interferon-free Treatment With Ledipasvir/Sofosbuvir (G1 and G4) and Sofosbuvir/Velpatasvir (G2 and G3) for Patients With Hepatitis C Virus-associated Indolent B-cell Lymphomas
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 May 2023
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 30 Mar 2023 Status changed from active, no longer recruiting to completed.
- 16 Jun 2022 Planned End Date changed from 1 May 2022 to 1 Feb 2023.
- 15 May 2020 Status changed from recruiting to active, no longer recruiting.